MINNEAPOLIS--(BUSINESS WIRE)--In a clinical trial supported by Medtronic, Inc. (NYSE: MDT), deep brain stimulation (DBS) significantly reduced seizure frequency among patients with medically refractory epilepsy with partial-onset seizures, a form of the neurological condition that does not respond well to antiepileptic drugs. The study, known as SANTE® (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy), is the only prospective, randomized, double-blind pivotal study to evaluate the use of Medtronic DBS for epilepsy. The findings were presented at the American Epilepsy Society (AES) Annual Meeting in Seattle by Robert Fisher, M.D., professor of neurology and director of Stanford Epilepsy Center and principal investigator for the SANTE study.
